7255-89-2

Usage

Uses

Used in Pharmaceutical Research:
1-Benzyl-N-(2-nitrophenyl)piperidin-4-amine is used as a research compound for exploring its biological activity and potential medicinal uses. Its unique molecular structure positions it as a candidate for further studies in drug development, particularly for the treatment of various medical conditions.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 1-Benzyl-N-(2-nitrophenyl)piperidin-4-amine is utilized as a key intermediate in the synthesis of new drugs. Its structural components allow for the design and modification of pharmaceutical agents that could address specific therapeutic needs.
Used in Drug Development:
1-Benzyl-N-(2-nitrophenyl)piperidin-4-amine is employed as a precursor in the development of drugs targeting specific medical conditions. Its potential as a pharmacological agent is being investigated for its efficacy and safety in treating diseases, making it a valuable asset in the creation of novel therapeutic solutions.

InChI:InChI=1/C18H21N3O2/c22-21(23)18-9-5-4-8-17(18)19-16-10-12-20(13-11-16)14-15-6-2-1-3-7-15/h1-9,16,19H,10-14H2

Upstream product

• 50541-93-0 4-amino-1-benzylpiperidine 
• 1493-27-2 ortho-nitrofluorobenzene 
• 88-73-3 2-Chloronitrobenzene 

Downstream Products

• 57718-47-5 N-(1-benzyl-piperidin-4-yl)-benzene-1,2-diamine 
• 16148-06-4 R 4782 

Relevant academic research and scientific papers

2-oxoimidazole derivatives

The present invention relates to a compound represented by Formula [I] wherein represents an aromatic carbo- or heterocyclic ring which may have a substituent; Cy represents a mono-, bi- or tricyclic aliphatic carbocyclic group having 3 to 20 carbon atoms, which may have a substituent; represents a mono- or bicyclic aliphatic nitrogen-containing heterocyclic group having 3 to 14 carbon atoms, which may have a substituent; R1represents a hydrogen atom, a lower alkenyl group, a lower alkynyl group, a cyclo(lower alkyl) group, an amino group, a lower alkylamino group, a di(lower alkyl)-amino group, a hydroxyl group, a lower alkoxy group, a carboxyl group, a lower alkoxycarbonyl group, a carbamoyl group, a lower alkylcarbamoyl group or a di(lower alkyl)carbamoyl group, or a lower alkyl group which may have a substituent; and R2represents a hydrogen atom or a lower alkyl group, a salt or ester thereof, a production process for the same, and an analgesic, a reliever against tolerance to a narcotic analgesic represented by morphine, a reliever against dependence on a narcotic analgesic represented by morphine, an analgesic enhancer, an antiobestic, a drug for ameliorating brain function, a remedy for schizophrenia, a remedy for Parkinsonism, a remedy for chorea, an antidepressant, a remedy for diabetes insipidus, a remedy for polyuria, or a remedy for hypotension, comprising an effective ingredient of the same.

From hit to lead. Combining two complementary methods for focused library design. Application to μ opiate ligands

Compound 1 obtained by random screening and displaying a micromolar activity on the μ opiate receptor was chosen as a starting point for optimization. Two complementary concepts of similarity were used for the design of analogues and compared. These are based, respectively, on a computer-aided comparison of pharmacophoric patterns and on topological similarity. The structure-activity relationships are discussed in light of both similarity concepts. Compound 40, an N-methyl-3-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decyl)acetamide derivative, designed by combining the structure-activity relationships enlightened by each method, has a subnanomolar affinity for μ (h) receptor (IC50=0.9 nM). It is a promising lead, allowing the design of a new series of analogues substituted at the N-3 of the spirocycle moiety.

Dipeptides which promote release of growth hormone

Compounds of formula (I) are growth hormone releasing peptide mimetics which are useful for the treatment and prevention of osteoporosis. STR1